Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need.
Our initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 is a co-stimulatory receptor that plays a central role in modulating the activation, proliferation, differentiation and trafficking of effector T cells that drive a number of immuno-inflammatory diseases. Itolizumab is a clinically-validated therapeutic that has demonstrated a favorable safety and tolerability profile. Equillium is advancing EQ001 into clinical development in multiple immuno-inflammatory indications with high unmet medical need and believes that EQ001 has the potential to be a best-in-class disease modifying therapeutic.
Chief Executive Officer
Chief Scientific Officer
Chief Medical Officer
Chief Financial Officer
Chief Operating Officer
SVP of Development Operations
Equillium acquired rights for developing and commercializing itolizumab in the U.S., Canada, Australia and New Zealand through an exclusive collaboration and license agreement with Biocon.